I V Kolerova

City Clinical Hospital No. 1 named after N.I. Pirogov, Moscow, Russia.

2 publications 2024 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does I V Kolerova research?

I V Kolerova studies how different treatments can help patients recover from ischemic stroke, which occurs when blood flow to the brain is blocked. One of the key medications they research is Revelise (alteplase), which is designed to dissolve clots and restore blood flow. Their work involves assessing both the effectiveness of this medication and its impact on patients' quality of life after treatment, especially in older adults or those with other health conditions.

Key findings

  • In the International PRIMA Study, nearly half of the 2,202 patients (49.9%) experienced good outcomes at discharge after receiving Revelise.
  • Follow-up after 90 days showed that the positive outcome rate increased to 66.4%, indicating a significant recovery for many patients.
  • The study highlighted that Revelise is effective in reducing stroke-related disabilities, even among older patients and those with additional health problems.

Frequently asked questions

Does Dr. Kolerova study ischemic stroke?
Yes, Dr. Kolerova specifically focuses on treatments for ischemic stroke.
What treatments has Dr. Kolerova researched?
Dr. Kolerova has researched the medication Revelise (alteplase) and its effects on stroke recovery.
Is Dr. Kolerova's work relevant to older patients?
Yes, Dr. Kolerova's research includes many older patients, showing that Revelise can effectively help this group.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

[Clinical and genetic associations in patients with non-cardioembolic ischemic stroke].

2024

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Galkin SS, Anisimova AV, Gunchenko AS, Nasedkina TV, Makhmudov MM +2 more

Plain English
This study looked at how genetic markers in patients who had a type of stroke not caused by heart issues affect their response to blood-thinning medication. Researchers examined 296 patients and found that those with certain genetic variations had different levels of platelet activity, which could influence their recovery. For example, patients with a specific genetic marker showed less platelet response, suggesting a link that can help tailor more effective treatments. Who this helps: This benefits patients who have experienced non-cardioembolic ischemic strokes by leading to better personalized treatments.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.